39762 - Disease and Disability Progression in Relapsing MS: Unpacking Efficacy Data to Advance Treatment Decisions

The evolving landscape of multiple sclerosis (MS) presents new challenges for clinicians as they strive to address the complexities of disease progression, neuroinflammation, and patient outcomes. Despite advances in treatment, the persistent burden of disease progression and disability accumulation remains a significant unmet need in MS care. Bruton’s tyrosine kinase (BTK) inhibitors represent an exciting, next-generation therapeutic class that targets both B cells and myeloid cells—critical players in MS pathology—offering hope for improved patient outcomes.

Join this PeerView Live event at ACTRIMS 2026 for a deep dive into how BTK inhibitors can reshape the management of MS. Hear directly from expert faculty as they share the latest clinical evidence, explore how these therapies can modify disease course, and guide you in personalizing treatment strategies for your patients. Don’t miss this opportunity to elevate your MS care with actionable insights and cutting-edge strategies.

This presentation is livestreamed from 7:00-8:00 PM EST.

There are no fees for participating in and receiving CME credit for this activity.

For more information, or to register, visit the PVI, PeerView website.

1. Summarize the shortcomings of available MS therapies and the need for approaches that target smoldering neuroinflammation;
2. Analyze efficacy and safety data for emerging BTK inhibitors in addressing MS progression and disability;
3. Formulate strategies for integrating BTK inhibitors into future MS treatment paradigms based on current evidence and clinical profiles.

Accreditation Statement
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Designation Statement
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Collaboration Statement
The University of Cincinnati and PVI, PeerView Institute for Medical Education are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners

PVI, PeerView Institute for Medical Education

Kim Nealy, PharmD, Medical Director

Laura Cooney, Managing Editor

Kim Phan, Senior Educational Program Manager

PeerView staff do not have any relationships to report.

University of Cincinnati Center for Continuous Professional Development/CME

Robert V. Ellis, MD Physician Reviewer

Jackie Knapke, PhD, Associate Dean

Heather Muskopf, Program Director

University of Cincinnati reviewers and staff do not have any relationships to report.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.